FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1562903670> ?p ?o ?g. }

• W1562903670 endingPage "86" @default.
• W1562903670 startingPage "81" @default.
• W1562903670 abstract "Diabetes is characterized by hyperglycaemia and by the development of complications. The criteria for diagnosis have been revised and published by the World Health Organization (WHO). In a symptomatic patient, a random plasma glucose concentration of ≥11.1 mmol l−1 is diagnostic. For asymptomatic patients, two diagnostic tests are required. A fasting glucose level ≥7 mmol l−1 confirms the diagnosis (providing this is supported by a second diagnostic test). The 75 g oral glucose tolerance test, as recommended by the WHO, is used for diagnosis in borderline cases or for academic studies. A plasma glucose concentration ≥11.1 mmol l−1 at 2 h following oral glucose confirms the diagnosis (Table 1). The microvascular complications specific to diabetes include retinopathy, nephropathy and neuropathy. Patients with diabetes are predisposed also to macrovascular disease (coronary heart disease, stroke and peripheral vascular disease). The macrovascular complications are not specific but occur with increased frequency in the diabetic compared with the nondiabetic population [1, 2]. Mortality from coronary heart disease (CHD) is 2–4 times higher than in the nondiabetic community. CHD is a problem for all diabetic patients but particularly for South Asian patients with diabetes whereas stroke is a problem especially for the African-Caribbean diabetic population [3-9]. Diabetes is a common disorder. Type 2 diabetes is much more common than Type 1 (insulin-dependent) and our discussion is confirmed to Type 2. In the adult population, the prevalence is 3–5% and in the population >65 years, this rises to 10%. It is commoner in non-European people in the UK than in Europeans (this ethnic difference is evident elsewhere). In the South Asian population >40 years, for example, the prevalence is 20–30%. Diabetes is also becoming more common and by the year 2010, more than 200 million people worldwide will have the disorder. Currently, diabetes consumes 5–15% of healthcare budgets in the developed world and most of this cost is due to the treatment of diabetic complications. As diabetes becomes more common in the developing world [10], it will have major implications for public health services and their costs. Impaired fasting glycaemia (IFG) refers to those in the population with a fasting plasma venous glucose concentration 6.1<7.0 mmol l−1. If an oral glucose tolerance test is performed, subjects with a 2 h plasma venous glucose level ≥7.8<11.1 mmol l−1 are classified as having impaired glucose tolerance (IGT). The importance of IFG and IGT is that these subjects, while not predisposed to the microvascular complications of diabetes, are at risk of macrovascular disease [11-13]. People with lesser degrees of glucose elevation frequently demonstrate other CHD risk factors, such as insulin resistance, central obesity, hypertension, elevated triglyceride concentrations and a reduction in HDL cholesterol [9, 14-16]. The Metabolic Syndrome (Syndrome X, Reaven's Syndrome) has been defined as abnormal glucose tolerance in association with insulin resistance, together with two or more of the following: blood pressure ≥160/90 mm Hg; triglyceride ≥1.7 and/or HDL cholesterol ≤0.9 mmol l−1; waist : hip ratio ≥0.90 and/or BMI ≥30 kg m−2; microalbuminuria ≥20 µg min−1. Patients with lesser degrees of glucose elevation, with or without the other components of the Metabolic Syndrome, are at risk of developing frank diabetes. The frequency of progression from IGT to diabetes, for example, ranges from 2% to 14% per year, depending on the ethnic origin of the population. IGT is a risk factor for CHD however, even independently of the development of diabetes, and many patients will die of CHD before becoming diabetic. Some of the measurements which are performed routinely in all patients with diabetes, and others which are reserved for research, are listed in Table 2. Measurement of glucose in urine has been possible for patients at home since the 1940s [reviewed in 17]. The initial Clinitest reagent tablets (a modification of Benedict's test) required the addition of the tablet in a tube. The chemical reaction caused urine glucose to be oxidized, reducing cupric sulphate to a colour ranging from blue to orange. This permitted semiquantitative results to be obtained by visual comparison with a colour chart. Reagent tablets were replaced by test strips in the 1950s. The Clinistix reagent strips were the first to be introduced and utilized glucose oxidase and peroxidase with a chromogen, covered by a semi-permeable membrane. A colour change was produced as glucose was oxidized. Again, a semi-quantitative result was obtained by inspection with a colour chart. Urine glucose testing systems remain widely used throughout the world. They have the advantage of being inexpensive and some patients find urine testing more acceptable than blood testing. They do rely on the renal threshold for glucose being constant (and there is some variability in this). Urine testing cannot help with the detection of hypoglycaemia. Home blood glucose monitoring became possible in the 1960s and this is the method most frequently utilized for home monitoring of diabetic control in the Western world. It is employed by most patients treated with insulin and by some Type 2 diabetic patients managed on diet with or without oral hypoglycaemic therapy. Blood glucose profiles, with glucose measurements extending from before breakfast until prebed, are useful to guide patients as to their optimum insulin therapeutic regimen. Typically, measurements are made on 2–6 occasions through the sampling period. Knowledge of the kinetics of insulin action, together with these glucose measurements, provides the basis for therapeutic adjustments. During intercurrent illness, patients are encouraged to test more frequently. It is usual for insulin requirements to increase at such times and knowledge of ambient glucose levels may permit satisfactory diabetic control to be obtained throughout the illness. Blood glucose measurements also provide information about hypoglycaemia. Such information is extremely useful to patients and their physicians when there is any doubt as to the cause of possible hypoglycaemic symptoms. Early test strips, such a Dextrostix, were semi-quantitative. They were read visually and were very useful. Their reliability did require satisfactory vision (which may not be the case in some diabetic patients) and required that the patient was capable of timing accurately the measurement after application of the blood to the test strip. The methods also required some manual dexterity, for example to satisfactorily remove red cells from the strip surface [18]. For this reason, other glucose measurement systems have been introduced. Reflectance meters were introduced at the end of the 1960s and through the 1970s. These meters measure light reflected from a coloured test strip, providing quantitative glucose estimations. Early machines were cumbersome and needed skilled usage. They required manual calibration and were sensitive to incorrect application of blood to the test strip. Recent systems are portable and compact, and require much less operator skill. Measuring the colour on the underside of the strip has removed the requirement for correct wiping technique at the end of the reaction period. Timing is automatic and there are in-built safeguards to warn that meter maintenance is required. Absorbance meters measured the absorption of light at a specific wavelength. The recently introduced HemoCue B system is a glucose home monitoring system which utilizes absorbance methodologies. It is one of the most accurate of all home glucose measurement devices. Biosensors became available in the late 1980s and into the 1990s. One of these, produced by MediSense, utilized glucose oxidase with ferrocene as the mediator. When glucose was oxidized to gluconolactone, the electrons released were absorbed by ferrocene to form ferrocinium, which was oxidized at an electrode. The current produced was proportional to the glucose concentration. These sensors were robust, as the electrodes to which blood was applied were external to the body of the equipment, and again effective blood wiping was not required. Circulating haemoglobin in normal adults comprises HbA, HbA2 and HbF (Figure 1). These three haemoglobin variants share an α chain, with specificity dictated by the non-α chain. Circulating haemoglobin variants. HbA1 was first observed on the basis of altered electrophoretic mobility in 1955 (excellent review in 19). HbA1 was subsequently resolved into three fractions, HbA1a, HbA1b and HbA1c. HbA1a was subsequently resolved into two components (HbA1a1, HbA1a2). It is the HbA1c moiety which has particular relevance to diabetes control. HbA1c is the product of a nonenzymatic reaction between glucose and the N-terminal valine of the β–globin chains. Biosynthesis of HbA1c is a slow process and the degree of glycation is dependent on the ambient glucose concentrations. In consequence, HbA1c levels are considered to reflect diabetic control over the preceding 6 to 8 week period. A variety of methods have been devised for measurement of glycosylated haemoglobin concentrations. 1a. Cation exchange chromatography Glycation of haemoglobin results in a small change in electrical charge of the haemoglobin molecule. This alters its migration in electric fields or cation exchange resins. Early column cation exchange methods suffered from poor reproducibility, interference by aldimine in blood and by lipids in lipaemic serum. Later methods, e.g. the Bio-Rad Laboratories HbA1c Bicolumn Test, managed to overcome many of these problems and were widely adopted. 1b. High performance liquid chromatography (h.p.l.c) Excellent cation exchange resin h.p.l.c. methods appeared later and provided rapid and reproducible assays which could be automated. In recent years, these methods have been automated, permitting high throughput as demand for HbA1c measurement has grown. Low pressure and high pressure systems have been devised with coefficients of variation (C.V.) of <3%. 1c. Electrophoresis The very small change in isoelectric point following glycosylation of haemoglobin (0.01 pH units) has required the development of specialized techniques. Agar gel electroendosmosis with detection of the separated bands by scanning densitometry provide reasonable quantification. This principle was adopted by a commercial kit (CIBA Corning) which was widely employed in the 1980s. This method has been largely replaced by more automated techniques. In recent years, improved electrophoretic methods capable of automation have been developed and are now widely employed (e.g. Diatrac; Beckman). 1d. Affinity chromatography and affinity separation The principle of this method is the binding of 1,2-cis diol groups on glycosylated haemoglobin to immobilized boronate, often on agarose gel. Mutual affinity chromatography methods have performed well in comparison with other methods. Inter-laboratory agreement has been less satisfactory, which might be an issue for external audit. Some variation in ligand concentration between batches may cause significant variations in results. Affinity h.p.l.c. methods have been developed to increase throughput and measure glycosylated haemoglobin with a C.V. of <3%. Conversion from total glycosylated haemoglobin to HbA1c values is necessary using a linear regression correlation. Automated methods (e.g. Abbott IMx) have been developed to give reproducible results and rapid analyses using disposable cartridges, permitting measurements in clinic (e.g. Glycosal Analyser, Provalis). 1e. Immunoassay methodologies An early enzyme immunoassay utilized a monoclonal antibody which detected the first 8 amino acids on the β-chain of haemoglobin, together with the attached glucose. The method is reproducible and correlates well with other methods but the reference range was lower than for other HbA1c methodologies. An immunoturbidimetric method utilizing an antibody which recognized the first four amino acids and glucose of the β-chain has proven robust (Roche Diagnostics Systems). A similar method employing proteolytic degradation to render the β-N terminal structure more accessible has been devised. A latex agglutination method, with the particles coated with HbA1c-specific monoclonal antibodies, has given good precision and correlation with other methodologies. This method has also been capable of in-clinic use. 1f. General issues Whichever method of glycosylated haemoglobin measurement is employed, its specificity is important. Measurement of HbA1c, aligned to the Diabetes Control and Complication Trial (DCCT) assay or to its successor from the International Federation of Clinical Chemistry, is essential [20]. HbA1c estimations will be utilized in future in auditing diabetic control between centres and standardization of results is essential for this purpose despite the fact that other factors influence the concentration [21]. The importance of glycosylated haemoglobin measurement results from the fact that they are uninfluenced by recent food ingestion and that they reflect integrated glucose concentrations over time. HbA1c reflects complication risk in the general population and in diabetic patients. In population studies, the risk of retinopathy increases with HbA1c concentrations between 6 and 7%, and is very low in those with values below 6%. Similarly, the risk of heart disease increases with increasing HbA1c levels, even in the general population, as illustrated in a recent study in Norfolk, UK [22]. In this Norfolk Study, the risk of death from CHD was increased 5-fold in those with an HbA1c >6.9% when compared with those in whom the HbA1c level was <5%. In patients with established Type 2 diabetes, the incidence of myocardial infarction increases with increasing HbA1c level, as does the incidence of microvascular end points [23]. 1g. Blood pressure Hypertension occurs with greater frequency in Type 2 diabetes than in the normal population [24]. Blood pressure, like blood glucose control, is predictive of cardiovascular events [25]. Effective treatment of blood pressure reduces the risk [26, 27]. In the diabetic subgroups of large blood pressure-lowering trials, the benefits of hypotensive treatment have been at least as good in diabetic patients as in the nondiabetic population. Cardiovascular events decreased in the diabetic patients, for example, by 51% in the HOT Study [28]. Reductions in the incidence of stroke and possibly myocardial infarction were noted in the United Kingdom Prospective Diabetes Study [29, 30]. 1h. Renal function and urinary albumin Diabetic nephropathy is characterized by persistent proteinuria, declining glomerular function and hypertension [31]. It is also associated with an increase in CHD risk. Nephropathy develops in both Type 1 and Type 2 diabetes. In Type 1 diabetes, the prevalence is 15–20% with a peak incidence after 15–16 years of diabetes. In Type 2 diabetes, prevalence rates of proteinuria have varied from 3% to 16%. The natural history of nephropathy in Type 2 diabetes is less well understood but, in view of the high prevalence of Type 2 diabetes compared with Type 1, almost 50% of all diabetic patients requiring renal replacement therapy have Type 2 disease. Clinical proteinuria is defined as urinary protein excretion of >500 mg day−1, equivalent to an albumin excretion of 300 mg day−1 (200 µg min−1). This phase of clinical proteinuria is preceded by a phase of microalbuminuria, when protein excretion is below the threshold of detection by Albustix, and must be measured by more sensitive methods. In Type 1 diabetes, 15–28% of patients have persistent microalbuminuria and in Type 2 patients, the proportion has been 15–59% in different series. The importance of proteinuria, as stated above, relates not merely to renal function but also to CHD and the relative cardiovascular mortality is increased 10-fold in patients with clinical nephropathy. CHD risk is increased even at the phase of microalbuminuria. 1i. Dyslipidaemia The typical dyslipidaemia of Type 2 diabetes is an increase in circulating triglyceride and a decrease in HDL cholesterol levels. The severity of the dyslipidaemia is predictive of vascular disease. Although total and LDL cholesterol concentrations may be in the range for the nondiabetic community, their concentrations correlate with CHD in Type 2 diabetic patients [32]. The relative severity of the triglyceride elevation and the HDL cholesterol suppression may be greater in women than in men [33]. Outcome data have shown the benefit of treatment of the dyslipidaemia. Early studies showed a reduced CHD event rate after 3 years of therapy with bezafibrate of dyslipidaemic patients with Type 2 diabetes (34). In the 4S Study, Simvastatin produced a 55% decrease and in the CARE Study, Pravastatin produced a 25% decrease in CHD events [35, 36]. We have focused on a small number of measurements which are widely performed. It is evident (Table 2) that others may become relevant. Certain patients develop CHD or microvascular disease quickly whereas others with apparently similar blood glucose and blood pressure control do not suffer complications over many years. The challenge is to find ways to distinguish those who require intensive risk factor intervention from those who are at lower risk. This is likely to involve biochemical and genetic approaches, and will ensure an exciting period of intensive research over the next decade." @default.
• W1562903670 created "2016-06-24" @default.
• W1562903670 creator A5020943069 @default.
• W1562903670 creator A5026004881 @default.
• W1562903670 creator A5089397114 @default.
• W1562903670 date "2002-06-28" @default.
• W1562903670 modified "2023-09-25" @default.
• W1562903670 title "What should we measure in the diabetic patient and how does this respond to therapy?" @default.
• W1562903670 cites W1545732697 @default.
• W1562903670 cites W1604542334 @default.
• W1562903670 cites W1862966 @default.
• W1562903670 cites W1979347922 @default.
• W1562903670 cites W1982880468 @default.
• W1562903670 cites W2004112113 @default.
• W1562903670 cites W2005761359 @default.
• W1562903670 cites W2010353121 @default.
• W1562903670 cites W2020825536 @default.
• W1562903670 cites W2033289265 @default.
• W1562903670 cites W2072734670 @default.
• W1562903670 cites W2075520007 @default.
• W1562903670 cites W2094910754 @default.
• W1562903670 cites W2100500261 @default.
• W1562903670 cites W2106603497 @default.
• W1562903670 cites W2123946565 @default.
• W1562903670 cites W2125157733 @default.
• W1562903670 cites W2125854867 @default.
• W1562903670 cites W2128864868 @default.
• W1562903670 cites W2137408480 @default.
• W1562903670 cites W2140854101 @default.
• W1562903670 cites W2144308372 @default.
• W1562903670 cites W2146158338 @default.
• W1562903670 cites W2152582537 @default.
• W1562903670 cites W2163949492 @default.
• W1562903670 cites W2302447233 @default.
• W1562903670 cites W2316375493 @default.
• W1562903670 cites W2322095705 @default.
• W1562903670 cites W2337454357 @default.
• W1562903670 cites W2529012027 @default.
• W1562903670 cites W3198570063 @default.
• W1562903670 cites W4244182132 @default.
• W1562903670 cites W50012954 @default.
• W1562903670 cites W82552949 @default.
• W1562903670 doi "https://doi.org/10.1046/j.1365-2125.2002.01624.x" @default.
• W1562903670 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1874395" @default.
• W1562903670 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12100231" @default.
• W1562903670 hasPublicationYear "2002" @default.
• W1562903670 type Work @default.
• W1562903670 sameAs 1562903670 @default.
• W1562903670 citedByCount "0" @default.
• W1562903670 crossrefType "journal-article" @default.
• W1562903670 hasAuthorship W1562903670A5020943069 @default.
• W1562903670 hasAuthorship W1562903670A5026004881 @default.
• W1562903670 hasAuthorship W1562903670A5089397114 @default.
• W1562903670 hasBestOaLocation W15629036702 @default.
• W1562903670 hasConcept C124101348 @default.
• W1562903670 hasConcept C134018914 @default.
• W1562903670 hasConcept C177713679 @default.
• W1562903670 hasConcept C2780009758 @default.
• W1562903670 hasConcept C41008148 @default.
• W1562903670 hasConcept C555293320 @default.
• W1562903670 hasConcept C71924100 @default.
• W1562903670 hasConceptScore W1562903670C124101348 @default.
• W1562903670 hasConceptScore W1562903670C134018914 @default.
• W1562903670 hasConceptScore W1562903670C177713679 @default.
• W1562903670 hasConceptScore W1562903670C2780009758 @default.
• W1562903670 hasConceptScore W1562903670C41008148 @default.
• W1562903670 hasConceptScore W1562903670C555293320 @default.
• W1562903670 hasConceptScore W1562903670C71924100 @default.
• W1562903670 hasIssue "1" @default.
• W1562903670 hasLocation W15629036701 @default.
• W1562903670 hasLocation W15629036702 @default.
• W1562903670 hasLocation W15629036703 @default.
• W1562903670 hasLocation W15629036704 @default.
• W1562903670 hasOpenAccess W1562903670 @default.
• W1562903670 hasPrimaryLocation W15629036701 @default.
• W1562903670 hasRelatedWork W1563850031 @default.
• W1562903670 hasRelatedWork W1989633716 @default.
• W1562903670 hasRelatedWork W2027089505 @default.
• W1562903670 hasRelatedWork W2415759662 @default.
• W1562903670 hasRelatedWork W2462738186 @default.
• W1562903670 hasRelatedWork W2899084033 @default.
• W1562903670 hasRelatedWork W2936087559 @default.
• W1562903670 hasRelatedWork W3036934084 @default.
• W1562903670 hasRelatedWork W4284965170 @default.
• W1562903670 hasRelatedWork W4288826408 @default.
• W1562903670 hasVolume "54" @default.
• W1562903670 isParatext "false" @default.
• W1562903670 isRetracted "false" @default.
• W1562903670 magId "1562903670" @default.
• W1562903670 workType "article" @default.